Restoring T-Cell Activity via PD-1 Blockade

How does PD-1 blockade restore T-cell activity in pembrolizumab-treated tumors?

PD-1 blockade restores T-cell activity by releasing PD-1-mediated suppression of preexisting exhausted tumor-infiltrating lymphocytes, enabling IFN-γ signaling that drives their clonal expansion, proliferation, and cytotoxic function.

Abstract

PD-1 blockade restores T-cell activity primarily through activation of preexisting tumor-infiltrating lymphocytes rather than recruitment of new T-cell clones. Across melanoma and head and neck cancer, restoration occurred via clonal expansion of exhausted CD8+ TILs with tissue-resident memory programs, increased CD8+ memory T cells, and enhanced granzyme B and Ki67 expression indicating proliferation and cytotoxic capacity. Mechanistically, this operated through release of PD-1-mediated suppression, enabling IFN-γ signaling pathways that drove T-cell proliferation, antigen presentation, and cytotoxic function. In head and neck cancer, restoration was further supported by enhanced K+ channel activity and Ca2+ signaling, which provided metabolic infrastructure for sustained T-cell activity. Restoration proceeded rapidly—within 5 weeks—through a biphasic pattern of immediate metabolic changes followed by durable functional enhancement. However, in pancreatic cancer, while PD-1 blockade successfully reactivated T cells as evidenced by increased cell cycle entry and IFNγ signature, concurrent upregulation of NF-κB signaling counteracted these benefits, demonstrating that successful restoration requires absence of alternative inhibitory pathways.

Baseline tumor immune composition determined restoration capacity across all cancer types studied. Responding tumors had higher baseline densities of CD8+, PD-1+, and PD-L1+ cells at tumor margins, preexisting ZNF683+CTX+ TILs, and T cell-inflamed gene expression signatures. The degree of T-cell restoration correlated directly with clinical outcomes, as proliferating intratumoral CD8+ T cells correlated with radiographic tumor reduction and enhanced functional measures associated with durable responses. These findings indicate that PD-1 blockade does not generate de novo antitumor responses but reinvigorates existing exhausted T cells, making adequate baseline T-cell infiltration a prerequisite for clinical benefit.

Methods

We analyzed 10 sources from an initial pool of 200, using 9 screening criteria. Each paper was reviewed for 8 key aspects that mattered most to the research question. More on methods

Results

Characteristics of Included Studies

All 10 sources examined T-cell restoration mechanisms following pembrolizumab treatment across diverse cancer types. The studies varied in cancer type, sample size, treatment protocols, and analytical approaches.

Mechanisms of T-Cell Restoration

Reversal of Exhaustion and Memory Cell Expansion

PD-1 blockade restored T-cell function primarily through reversal of exhaustion in preexisting tumor-specific T cells. In HNSCC, responding tumors contained clonally expanded exhausted CD8+ TILs with tissue-resident memory programs characterized by high cytotoxic potential (CTX+) and ZNF683 expression at baseline. Treatment activated these preexisting CTX+ZNF683+CD8+ TILs, paralleling loss of viable tumor. This revival of preexisting ZNF683+CTX+ TILs was identified as a major mechanism of response.

Across melanoma studies, CD8+ memory T cells emerged as the most prominent phenotype expanded intratumorally following PD-1 blockade. The frequency of T cells increased significantly in responding patients, with expansion specifically concentrated in CD8 T memory subsets. This expansion was accompanied by increased granzyme B and Ki67 expression in CD8 T cell subsets, indicating enhanced cytotoxic potential and proliferation. An early wave of proliferation gave rise to a pool of re-invigorated CD8 T cells.

Predictive Biomarkers for T-Cell Restoration

Baseline Immune Signatures

Baseline immune phenotypes strongly predicted restoration capacity. In HNSCC, high numbers of CD103+PD-1+CD8+ T cells infiltrating pretreatment lesions predicted response. The presence of ZNF683+CD8+ T cells with high cytotoxic potential and tissue-resident memory programs at baseline distinguished responders from nonresponders. Conversely, nonresponder baseline tumor microenvironments exhibited relative absence of ZNF683+CTX+ TILs.

In metastatic urothelial cancer, responders had higher baseline fractions of CD4+ T cells expressing cosignaling receptors and higher baseline density of T helper-type 1 (Th1) cells (T-bet+ CD4+ T cells) compared to nonresponders.

Across melanoma studies, higher numbers of CD8+, PD-1+, and PD-L1+ cells at the invasive tumor margin and tumor center at baseline predicted response. A predictive model based on CD8 expression at the invasive margin was established and validated in an independent cohort.

Conclusion

The restoration process exhibited coordinated spatiotemporal dynamics. Within tumors, CD8+ T-cell proliferation occurred in parallel at invasive margins and tumor centers. While early KCa3.1 effects were transient, Kv1.3 activity persisted after tumor resection, suggesting initial metabolic changes enabled sustained functional improvements. This biphasic pattern—rapid metabolic priming followed by durable functional enhancement—explains how checkpoint blockade can produce long-lasting responses from short treatment courses.